Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

1037 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of 100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of the pancreas) after endoscopic retrograde cholangiopancreatography (ERCP) in high risk patients. However, the optimal dose required is not known. The purpose of this study is to determine whether a dose of 200 mg, administered as rectal suppositories, is more effective than the standard dose of 100 mg. An ERCP procedure is a scope procedure where a lighted tube with a camera is passed down the patient's throat and allows for evaluation of the bile duct and/or pancreatic duct. The most common side effect of this procedure is post-ERCP pancreatitis, or swelling of the pancreas. Some patients are at higher risk for this complication than others. Our hypothesis is to compare the efficacy of these two dose regimens (100 mg vs 200 mg) of prophylactic rectally-administered indomethacin on the frequency and severity of post-ERCP pancreatitis in high-risk patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

NCT00727740

Pancreatitis

COMPLETED NA

Indomethacin Decreases Post-ERCP Pancreatitis

NCT02110810

Post ERCP Acute Pancreatitis

COMPLETED PHASE3

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

NCT03713879

Post ERCP Pancreatitis

RECRUITING PHASE3

Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac

NCT05947461

Post-ERCP Acute Pancreatitis NSAIDs Indomethacin +2 more

TERMINATED NA

Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis

NCT02476279

Post-ERCP Pancreatitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After obtaining informed consent, subjects will undergo ERCP per clinical protocol. All procedure-related clinical decisions and interventions will be dictated by the performing physician as he or she sees fit. At the end of the procedure, it will be determined by the endoscopist and research coordinator whether the patient meets inclusion criteria. If inclusion criteria are met, subjects will be randomized by concealed allocation to receive either 100mg or 150mg indomethacin, in the form of two or three 50mg rectal suppositories. Those patients who are randomized to receive the 100mg dose will receive an additional glycerin suppository. Four hours later, those patients who were randomized to the high-dose group will then receive an additional 50mg suppository while in the recovery area. At this same time point, subjects who were randomized to the standard-dose group, will receive a glycerin suppository in the recovery area. All participating patients will receive a total of 4 suppositories.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-ERCP Pancreatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high-dose indomethacin

200mg rectal indomethacin

Group Type EXPERIMENTAL

high dose indomethacin

Intervention Type DRUG

patients randomized to this intervention receive 200mg indomethacin

standard dose indomethacin

100mg rectal indomethacin

Group Type ACTIVE_COMPARATOR

standard dose indomethacin

Intervention Type DRUG

patients randomized to this intervention receive 100mg indomethacin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

high dose indomethacin

patients randomized to this intervention receive 200mg indomethacin

Intervention Type DRUG

standard dose indomethacin

patients randomized to this intervention receive 100mg indomethacin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Indocin Indocin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Included patients are those undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and have:

one of the following:

1. Clinical suspicion of sphincter of Oddi dysfunction (SOD; type I or II)
2. History of post-ERCP pancreatitis (at least one episode)
3. Pancreatic sphincterotomy
4. Pre-cut (access) sphincterotomy
5. greater than 8 cannulation attempts of any sphincter
6. Pneumatic dilation of intact biliary sphincter
7. Ampullectomy 8.) Assessment for post-sphincterotomy stenosis

OR at least 2 of the following:

1. Age less than 50 years old and female gender
2. History of recurrent pancreatitis (at least 2 episodes)
3. greater than or equal to to 3 pancreatic injections, with at least 1 injection to tail
4. Pancreatic acinarization (excluding ventral pancreas of pancreas divisum)
5. Pancreatic brush cytology -

Exclusion Criteria

1. Unwillingness or inability to consent for the study
2. Age less than 18 years
3. Intrauterine pregnancy
4. Breastfeeding mother
5. Standard contraindications to ERCP
6. Allergy/hypersensitivity to aspirin or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
7. Received NSAIDs in prior 7 days (aspirin 325mg or less ok)
8. Renal failure (serum creatinine greater than 1.4)
9. Active or recurrent (within 4 weeks) gastrointestinal hemorrhage
10. Acute pancreatitis (lipase peak) within 72 hours
11. Known chronic calcific pancreatitis
12. Pancreatic head mass
13. Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas divisum (dorsal duct not attempted on injected)
14. ERCP for biliary stent removal or exchange without anticipated pancreatogram
15. Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram
16. Anticipated inability to follow protocol
17. Known active cardiovascular or cerebrovascular disease -

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No